Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Non-Current Deffered Revenue (2016 - 2018)

Cardiff Oncology (CRDF) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $1.1 million as the latest value for Q4 2018.

  • Quarterly Non-Current Deffered Revenue fell 7.86% to $1.1 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2018, down 7.86% year-over-year, with the annual reading at $1.1 million for FY2018, 7.86% down from the prior year.
  • Non-Current Deffered Revenue hit $1.1 million in Q4 2018 for Cardiff Oncology, down from $1.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.4 million in Q3 2016 to a low of $1.0 million in Q2 2018.
  • Historically, Non-Current Deffered Revenue has averaged $1.2 million across 3 years, with a median of $1.2 million in 2017.
  • Biggest five-year swings in Non-Current Deffered Revenue: fell 20.29% in 2017 and later increased 4.4% in 2018.
  • Year by year, Non-Current Deffered Revenue stood at $1.4 million in 2016, then fell by 13.83% to $1.2 million in 2017, then decreased by 7.86% to $1.1 million in 2018.
  • Business Quant data shows Non-Current Deffered Revenue for CRDF at $1.1 million in Q4 2018, $1.2 million in Q3 2018, and $1.0 million in Q2 2018.